{"id":"gonal-f-rff","safety":{"commonSideEffects":[{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Injection site reactions (pain, bruising, redness)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain or bloating"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201692","moleculeType":"Protein"},"_dailymed":{"setId":"b6d11c45-b502-478e-bb28-2ff596ea259c","title":"GONAL-F RFF REDI-JECT (FOLLITROPIN) INJECTION, SOLUTION [EMD SERONO, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FSH binds to FSH receptors on granulosa cells of ovarian follicles, promoting follicular development and estrogen production. This leads to the growth of multiple follicles suitable for retrieval during assisted reproductive procedures such as in vitro fertilization (IVF). The RFF formulation is a ready-for-use pen device containing recombinant FSH.","oneSentence":"Gonal-f RFF is a recombinant human follicle-stimulating hormone (FSH) that stimulates the growth and maturation of ovarian follicles in women undergoing fertility treatment.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:11.274Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Infertility in women undergoing assisted reproductive technology (ART) including in vitro fertilization (IVF)"},{"name":"Anovulation in women with polycystic ovary syndrome (PCOS) or other causes of anovulation"}]},"trialDetails":[{"nctId":"NCT02459418","phase":"PHASE1","title":"Comparative Pharmacokinetics of AFOLIA and US Gonal-f® RFF Redi-ject After Single Subcutaneous Application","status":"COMPLETED","sponsor":"Fertility Biotech AG","startDate":"2015-05-07","conditions":"Healthy Volunteers","enrollment":42},{"nctId":"NCT01687712","phase":"PHASE3","title":"Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF","status":"COMPLETED","sponsor":"Fertility Biotech AG","startDate":"2013-11-25","conditions":"Infertility","enrollment":1100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Follitropin-alfa"],"phase":"marketed","status":"active","brandName":"Gonal-f® RFF","genericName":"Gonal-f® RFF","companyName":"Fertility Biotech AG","companyId":"fertility-biotech-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gonal-f RFF is a recombinant human follicle-stimulating hormone (FSH) that stimulates the growth and maturation of ovarian follicles in women undergoing fertility treatment. Used for Infertility in women undergoing assisted reproductive technology (ART) including in vitro fertilization (IVF), Anovulation in women with polycystic ovary syndrome (PCOS) or other causes of anovulation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}